HU-LUYE@EC2610B

Green Leaf Pharmaceutical Initiates PK Bridging Clinical Trial for LY03015 in the US

Citi Downgrades Lunan Pharma Revenue and Profit Forecasts, Maintains 'Buy' Rating

UBS Increases Stake in Luoxin Pharmaceutical to 10.09%

Green Leaf Pharmaceutical's Innovative Drug LY03020 Completes First Patient Enrollment in Phase II Clinical Trial in China

LUYE PHARMA released FY2025 Q3 earnings on March 30, 2026 (BJT), with actual revenue of HKD 1.709 B and EPS of HKD 0.0414

LUYE PHARMA released FY2025 9 Months Earnings on March 30 (BJT), actual revenue HKD 5.154 B, actual EPS HKD 0.1315

LUYE PHARMA released FY2025 Q4 earnings on March 30 During-Market (BJT), actual revenue HKD 1.739 B, actual EPS HKD 0.0421

LUYE PHARMA released FY2025 annual earnings on March 30 During-Market (BJT), actual revenue HKD 6.895 B (forecast HKD 7.359 B), actual EPS HKD 0.1735 (forecast HKD 0.1753)

LUYE PHARMA to Release FY2025 Earnings on March 30 During-Market (BJT), Forecast Revenue HKD 7.486 B, EPS HKD 0.1784

Green Leaf Pharmaceutical Completes Equity Repurchase with High-Yield Bet Terms and Investor Introduction

Green Leaf Pharma Injects 285 Million Yuan into Nanjing Greenleaf

Luye Pharma Group Issues Convertible Preferred Shares and Transfers Bona Bio Shares

Luoye Pharmaceutical Obtains Approval for Ruoxinlin® for Generalized Anxiety Disorder

Leaves Pharmaceutical Subsidiary Nangjing Lily Shareholder Withdraws, 25% Equity Transfer to Nangjing Xinshi

Green Leaf Pharmaceuticals Authorizes Lunan to Exclusively Commercialize Three Long-Acting Antipsychotic Injectable Products in Mainland China

Luye Pharma Grants Jiangsu Nanhua and Xin Pharmaceutical Exclusive Rights to Market Long-Acting Injectable Antipsychotic Drugs

Luye Genenno Holding Issued Convertible Preferred Shares to Bluebell Asset

Green Leaf Pharmaceutical's Five New Products Successfully Included in National Health Insurance Directory and Commercial Health Insurance Innovative Drugs Directory

Qilu Pharmaceutical Proactively Lowers Price of Aflibercept to Capture Market Share

Luye Pharmaceutical's New Drug LY03017 Receives FDA Clinical Trial Approval

DATRONIX HOLD

ALPHA PRO HLDGS

PRODUCTIVE TECH

INVESTECH HLDGS

QIANHAI HEALTH

SHANGSHAN GOLD

KIMOU ENVIRON

GUOXIA TECH

YUXING INFOTECH

HUA HONG SEMI

02186

05818

In a report released yesterday, from SDIC Securities maintained a Buy rating on Luye Pharma Group, with a price target of HK$4.34.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Luye Pharma Group is a Moderate Buy with an average price target of HK$4.31.

Tip Ranks

LUYE PHARMA

LUYE PHARMA POFF

LUYE PHA B2807

Luye Pharma Group (LYPHF) Receives a Buy from SDIC Securities

06636

02650

00568

09973

03625

00175

02333

00290

02315

EXTREME VISION(06636) rose 20.12%, with a trading turnover 255.1 Million HKD, and a year-to-date rose 149.3%. ZHIDA TECH(02650) rose 16.75%, with a trading turnover 19.3 Million HKD, and a year-to-date fell 21.7%. SHANDONG MOLONG(00568) rose 16.37%, with a trading turnover 3.9 Billion HKD, and a year-to-date rose 191.5%.

Top Gainers & Losers

EXTREME VISION

ZHIDA TECH

SHANDONG MOLONG

CHERY AUTO

FOURSEMI

GEELY AUTO

GWMOTOR

GOFINTECH QUANT

BIOCYTOGEN-B

Top 10 HK Stock Gainers (4.2)

01530

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. 

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. 

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. 

For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

Technical Forecast

3SBIO

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

159837

520880

159992

159316

510660

520690

513700

Luye Pharma Group has announced a RMB285 million capital injection into its subsidiary, Nanjing Luye, through a structured deal involving Nanjing Xinan and Ningbo Cinda. This investment will leave Luye Pharma with a 70.01% stake in the subsidiary. The deal includes equity option agreements allowing Luye’s affiliate to buy out new investors' stakes. This transaction is classified as a deemed partial disposal under Hong Kong listing rules, highlighting Luye's flexible financing strategy while maintaining control over its Nanjing operations. The current analyst rating for Luye Pharma stock is a Hold with a price target of HK$3.00.

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal

603368

Reuters

GUANGXI LIUYAO GROUP

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi

560600

512010

512290

06955

513120

159892

516500

513060

159506

159102

588130

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

BOAN BIOTECH

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Research Sector 100 ETF

Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal

BOAN BIOTECH announced that its controlling shareholder LUYE PHARMA plans to arrange for its wholly-owned subsidiary Shandong Luye Pharma to further transfer 38.5 million H shares in the market on Thursday (22nd) as part of the proposed transfer. In December last year, LUYE PHARMA's wholly-owned subsidiary Luye Geneora issued several exchangeable preferred shares, allowing preferred shareholders to exchange the relevant shares for the existing H shares held by LUYE PHARMA, involving 100.5 million shares

AASTOCKS

BOAN BIOTECH's controlling shareholder plans to further transfer 38.5 million shares

HU-LUYE@EC2610B(28248.HK)

HU-LUYE@EC2610B Stock Performance Chart

Luye Pharma Group (LYPHF) Receives a Buy from SDIC Securities

Top 10 HK Stock Gainers (4.2)

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi